Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments
Journal of Pharmaceutical and Biomedical Analysis · 2024
DOI: 10.1016/j.jpba.2024.116141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2024. Verfasst von Guillaume Rey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland. Hauptthemen laut MEDLINE: Enzyme-Linked Immunosorbent Assay. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Potency assays are essential for the development and quality control of biopharmaceutical drugs, but they are often a time limiting factor due to manual handling steps and consequently low analytical throughput. On the other hand, automation of potency assays can be challenging due to their complexity and the use of biological materials. ELISA (enzyme-linked immunosorbent assay) is widely used for potency determination and is a good candidate for automation as all ELISA types depend on the same basic steps: coating, blocking, sample incubation, detection, and signal measurement. Nevertheless, ELISA for relative potency measurements still require drug-specific development and assay validation thereby complicating automation efforts. To simplify potency testing by ELISA, we first developed a manual protocol generally applicable to different drugs and then adapted this protocol for automated measurements. We identified unexpected critical parameters which had to be adapted to transfer the manual ELISA to an automated liquid handling system and we demonstrated that gravimetric sample dilution is unnecessary with the automated protocol. Both manual and automated protocols were validated and compared using multiple biotherapeutics. The automated protocol showed similar or higher precision and accuracy when compared to the manual method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland.
- Current address: EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
- Current address: Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a. d. R., Germany.
- Current address: TA Oncology, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland. Electronic address: petr.obrdlik@novartis.com.
Förderung
- Novartis
Zitieren
APA
Rey, G., Schuetz, F., Schroeder, D., Kaluschke, C., Wendeler, M. W., Hofmann, I., Dumbliauskas, E., & Obrdlik, P. (2024). Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116141
Vancouver
Rey G, Schuetz F, Schroeder D, Kaluschke C, Wendeler MW, Hofmann I, et al. Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments. Journal of Pharmaceutical and Biomedical Analysis. 2024. doi:10.1016/j.jpba.2024.116141
BibTeX
@article{Rey2024,
author = {Rey, Guillaume and Schuetz, Fabienne and Schroeder, Daniela and Kaluschke, Christian and Wendeler, Markus W and Hofmann, Irmgard and Dumbliauskas, Eva and Obrdlik, Petr},
title = {Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2024},
doi = {10.1016/j.jpba.2024.116141}
}
EUVIMED